title: Oral antioxidants supplementation for women with unexplained infertility undergoing ICSI/IVF: randomized controlled trial.
abstract: OBJECTIVE
  Good oocyte quality and maturity are important prerequisites for high fertilization and implantation rates in IVF/ICSI treatment cycles. Reactive oxygen species (ROS) are produced within ovarian follicles, especially during the ovulation process, and increased ROS activity may be a cause of impaired oocyte maturation and higher rate of failure of IVF/ICSI cycles.
  
  
  METHODS
  RCT evaluating the effect of antioxidant supplementation on ICSI/IVF outcomes. Two hundred and eighteen women with unexplained subfertility undergoing IVF/ICSI were randomized into two groups. The study group (n = 112) received daily oral antioxidants in the form of multivitamins and minerals (amino acid chelated) while the control group (n = 106) did not. Main outcomes were number of mature metaphase II (MII) oocytes and clinical pregnancy rate.
  
  
  RESULTS
  There were no significant changes between the groups as regards age, BMI, basal FSH, number of mature (MII) oocytes (12.7 ± 9.4 vs. 13.2 ± 8.6, P = 0.7) and clinical pregnancy rate per woman randomized (38% vs. 34%; [OR = 1.2; 95% CI, 0.70-2.11].
  
  
  CONCLUSIONS
  Oral antioxidants in the form of a combination of multivitamins and minerals (amino acid chelated) did not improve oocyte quality and pregnancy rates in women with unexplained infertility undergoing IVF/ICSI treatment.
authors.affiliation: Department of Obstetrics and Gynaecology, Faculty of Medicine, Cairo University , Cairo , Egypt.
authors.forename: Mohamed A F M
authors.initials: MA
authors.lastname: Youssef
authors.forename: Hatem I
authors.initials: HI
authors.lastname: Abdelmoty
authors.forename: Hazem A
authors.initials: HA
authors.lastname: Elashmwi
authors.forename: Esaad M
authors.initials: EM
authors.lastname: Abduljawad
authors.forename: Nevin
authors.initials: N
authors.lastname: Elghamary
authors.forename: Ahmed
authors.initials: A
authors.lastname: Magdy
authors.forename: Mohamed N
authors.initials: MN
authors.lastname: Mohesen
authors.forename: Rana M A
authors.initials: RM
authors.lastname: Abdella
authors.forename: Mostafa Abdel
authors.initials: MA
authors.lastname: Bar
authors.forename: Hisham M
authors.initials: HM
authors.lastname: Gouda
authors.forename: Ahmed Mahmoud Sayed
authors.initials: AM
authors.lastname: Ali
authors.forename: Ayman N
authors.initials: AN
authors.lastname: Raslan
authors.forename: Dalia
authors.initials: D
authors.lastname: Youssef
authors.forename: Nadin A
authors.initials: NA
authors.lastname: Sherif
authors.forename: Aboulfoutouh I
authors.initials: AI
authors.lastname: Ismail
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D002614:Chelating Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019587:Dietary Supplements; D004534:Egypt / Q000453:epidemiology; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology; D005307:Fertilization in Vitro; D005500:Follow-Up Studies; D006801:Humans; D007247:Infertility, Female / Q000178:diet therapy* / Q000503:physiopathology / Q000628:therapy; D059012:Lost to Follow-Up; D054315:Oocyte Retrieval; D009866:Oogenesis / Q000187:drug effects; D010062:Ovulation Induction / Q000009:adverse effects*; D018384:Oxidative Stress; D011247:Pregnancy; D018873:Pregnancy Rate; D020554:Sperm Injections, Intracytoplasmic; D014131:Trace Elements / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D002614:Chelating Agents; D005300:Fertility Agents, Female; D014131:Trace Elements; D014815:Vitamins
keywords: Antioxidants; IVF/ICSI; ovarian stimulation